Effect of unani medicine in patients with Eczema

Clinical Study Of Nar-E-Farsi(Eczema) And Its Effective Management With Unani Medicine - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/11/060053

Enrollment

Registered

2023-11-21

Start date

Unknown

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L208- Other atopic dermatitis

Interventions

Intervention1: Unani drug: 2gm tid po for 30 days and ointment for local application Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Both sex Itching Erythema Scaling

Exclusion criteria

Exclusion criteria: 1 Any systemic illness 2 Pregnant and lactating and others 3 Mentally retarded patients

Design outcomes

Primary

Measure	Time frame
Primary outcome depend on relief of itching as per Eczema Area Severity IndexTimepoint: O 10th day 20th day 30th day	—

Secondary

Measure	Time frame
Primary outcome depend on relief of itching as per Eczema Area Severity IndexTimepoint: It can be assess with in a period of 30 days	—

Countries

India

Contacts

Public ContactDr Syeda Mariya Hassan

Govt Nizamia Tibbi College and General Hospital.

dr.faroqui@gmail.com9849139356

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026